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Abstract Pharmacokinetic (PK) software packages 
are widely used by scientists in different disciplines 
to estimate PK parameters. However, their use 
without a clear understanding of physiological 
parameters affecting the PK parameters and how 
different PK parameters are related to each other 
may result in erroneous interpretation of data. 
Often, mathematical relationships used for the 
estimation of PK parameters obscure the true 
physiological relationships among these parameters, 
prompting a discussion of which parameter came 
first and giving the appearance of the-chicken-and-
the-egg dilemma. In this article, the author attempts 
to show how different PK parameters are related to 
physiological parameters and each other by using 
various scenarios and examples. In particular, the 
relationship between clearance and the rate of 
elimination and that among the other major PK 
parameters are explored. It is concluded that there is 
no dilemma in interdependency of the PK 
parameters, and the relationships among the PK 
parameters and between PK and physiological 
parameters are clear. 
INTRODUCTION 
The origin of pharmacokinetics is attributed to an 
article written by Torsten Torell in 1937 (1). After 
an initial fascination with mathematical 
relationships defining this discipline, came the 
introduction of a large number of easy-to-use 
pharmacokinetic (PK) software packages. Because 
of widespread application of pharmacokinetics in 
other disciplines, such as biology, pharmacology, 
and physiology, and the availability of software, the 
use of pharmacokinetics in biological sciences has 
grown substantially in the last two decades. 
However, the use of the PK software without a clear 
understanding of physiological parameters affecting 
the PK parameters and how different PK parameters 
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are related to each other may result in erroneous 
interpretation of data. 
 One of the most common errors made by 
biological scientists, whose main focus and 
education are not in the area of pharmacokinetics, is 
the distinction between mathematical and 
physiological relationships among PK parameters 
(2). In other words, when two PK parameters are 
changed, which parameter is the cause and which 
one is the effect. For example, a recent heated 
discussion was erupted among some of the 
subscribers to the PharmPK LISTSERV† about 
whether the clearance of a drug is dependent on the 
rate of elimination or vice versa, with apparently no 
final resolution. The advocates of the dependency 
of CL on the rate of elimination (dAe/dt) cited the 
following equation as evidence: 
CL =
dAe /dt
C
 (1) 
 The argument is that because in practice, CL is 
sometimes determined from the rate of elimination, 
it is obvious that the latter influences the former. 
The proponents of the dependency of the rate of 
elimination to CL, on the other hand, state that the 
correct physiological presentation of the above 
equation is: 
dAe /dt = CL × C  (2) 
with a definition of CL as the proportionality 
constant relating the rate of elimination to the blood 
concentration. This group argues that although in 
practice CL may be estimated using Equation 1, it is 
the rate of elimination that is dependent on CL, not 
vice versa.  
 This may seem a matter of semantics or give 
the impression of the-chicken-and-the egg dilemma. 
However, neither is true because there is indeed a 
clear physiologic cause and effect relationships 
among PK parameters, including clearance and rate 
of elimination, as demonstrated in the following 
sections.  
 It should be noted that the concepts presented 
here are not new and have been known by 
pharmacokineticists for many years. However, the 
aim of this presentation is to highlight the 
interdependence of PK parameters in an integrated 
and focused manner with some examples. 
                                                     
† A Listserv maintained by Dr. David Bourne at the University of 
Oklahoma (http://www.boomer.org/pkin/). The message thread 
was “Clearance and Elimination.” 
J Pharm Pharmaceut Sci (www.cspsCanada.org) 9(1):113-118, 2006 
 
 
 
 
114 
THE RELATIONSHIP BETWEEN CLEARANCE 
AND RATE OF ELIMINATION 
For illustration purposes, we shall select a 
hypothetical drug with elimination through hepatic 
metabolism only, although the same principles are 
valid for drugs with exclusive renal elimination or a 
combination of renal and hepatic elimination. 
Figure 1 demonstrates the cellular events in the 
liver that lead to the metabolism of drugs.  
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fub Q
CLint = KM+CU
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Figure 1: Factors affecting the metabolism of a 
hypothetical drug by the liver enzymes. 
 
The intrinsic capability of the liver enzymes in the 
hepatocytes to metabolize the drug (CLint) is 
dependent on the Michaelis-Menten constants, VMAX 
(maximum rate of metabolism) and KM (drug 
concentration producing half of VMAX), and drug 
concentration at the site of metabolism (Cu) as 
defined by the following equation: 
CLint =
VMAX
KM + Cu
 (3) 
 For majority of drugs, therapeutic 
concentrations result in Cu values much lower than 
KM, hence for these drugs CLint becomes a constant 
independent of the blood concentrations within the 
therapeutic range: 
CLint ≈
VMAX
KM
 (4) 
 This is not true for drugs such as phenytoin 
where therapeutic concentrations are close to the KM 
values. For these drugs, CLint decreases with an 
increase in the blood concentrations. For simplicity, 
we shall assume that our drug is metabolized by a 
single enzyme with a VMAX of 1.5 mg/min and a KM 
of 0.1 mg/L. Further, its therapeutic concentration 
ranges from 1 to 10 µg/L and its free fraction in 
blood (fub) is 0.1. This means that at therapeutic 
concentrations, the free drug concentrations (Cu) 
(0.1-1 µg/L) are much lower than KM (0.1 mg/L). 
Therefore, linear metabolism is expected within this 
range as CLint stays close to 15 L/min: 
CLint ≈
1.5 mg/min
0.1 mg/L
≈15 L/min  (5) 
 It should be noted that this parameter (CLint) is 
the intrinsic capability of the liver to remove the 
drug in the absence of any supply (liver blood flow) 
limitation. However, as demonstrated in Fig. 1, the 
access of the liver enzymes to the drug is limited by 
other parameters such as the liver blood flow (Q), 
free fraction of the drug in the blood (fub), and 
permeability of the hepatocytes to the drug. 
However, in most cases, permeability of the 
hepatocytes to the drug is not the rate-limiting step 
in the metabolism of most drugs. 
 In the following sections, we will look at the 
metabolism of this hypothetical drug at a macro 
level by presenting three different scenarios.  
Scenario 1: the basics 
The metabolism of our hypothetical drug during 
one pass through the liver is depicted in Fig. 2.  
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Metabolite
Q: 1.5 L/min
Cin: 6 µg/L
Cout: 3 µg/L
 
 
Figure 2: The metabolism of a hypothetical drug in one 
single pass through the liver based on Scenario 1 (see 
text for details). 
 
For demonstration purposes, we assume that the 
concentrations of the drug entering and leaving the 
liver are 6 and 3 µg/L, respectively. This indicates 
that 50% of the drug entering the liver is converted 
to a metabolite or, in other words, the fraction of the 
drug extracted by one single-pass through the liver 
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(extraction ratio, E) is 0.5. As demonstrated in Fig. 
1, assuming high permeability, the extraction ratio 
(E) is dependent on Q, fub, and CLint. Several models 
have been proposed (3-5) to define the relationship 
between E and its three determinants. One of the 
widely-used models is the well-stirred or venous 
equilibrium model, which defines this relationship 
using the following equation (3): 
E ≈
fub ⋅ CLint
Q + fub ⋅ CLint
=
0.1×15
1.5 + (0.1×15)
= 0.5 (6) 
 Considering that the blood leaving the liver 
contains a concentration half of that entering the 
liver (Cin) (Fig. 2), one may state that half of the 
blood is totally cleared of the drug and the other 
half has the same concentration as Cin. In other 
words, half of the blood is cleared of the drug per 
unit of time. This is one of the definitions of 
clearance, which in this case is equivalent to 0.75 
L/min (0.5 x 1.5 L/min), forming the basis of the 
following equation: 
CL = Q × E  (7) 
 Equations 6 and 7 clearly indicate both E and 
CL are dependent on fub, CLint, and Q. Substituting 
Equation 4 and 6 into 7 would clearly show the 
determinants of CL for a drug with linear 
metabolism: 
CL = Q ⋅
fub ⋅
VMAX
KM
Q + fub ⋅
VMAX
KM
 (8) 
 Any change in Q, fub, VMAX, and/or KM may 
potentially affect the CL of the drug. The degree of 
dependency of CL on any of these parameters, 
however, is influenced by the initial values of these 
parameters relative to each other, and its discussion 
is outside the scope of this communication. 
 Now that we have dealt with CL, let us consider 
the rate of elimination in our example (Fig. 2). 
Considering a Q of 1.5 L/min and the inlet and 
outlet concentrations of 6 and 3 µg/L, respectively, 
this means that the rate of elimination (metabolism) 
of the drug is 4.5 µg/min (1.5 L/min x 3 µg/L). The 
same value may also be obtained using Equation 2: 
dAe /dt = CL × C = 0.75 L/min× 6 μg/L = 4.5 μg/min
 
Scenario 2: a change in the blood concentration 
Let us assume that the drug concentration entering 
the liver is now changed from 6 µg/L to 4 µg/L 
(Fig. 3). Because of the linear metabolism of the 
drug, the change in Cin is not expected to affect 
CLint, Q, or fub of the drug. Therefore, as Equation 6 
suggests, the E of the drug (0.5) does not change. 
Consequently, the outlet concentration will be 2 
µg/L in this case (Fig. 3). The CL of the drug, 
defined as the volume of blood cleared of drug per 
unit of time, also remains the same as that in 
Scenario 1 (0.75 L/min, Fig. 3). This is also 
consistent with the calculation of CL based on 
Equation 7 or 8, as none of the determinants of CL 
were changed. However, the rate of elimination of 
the drug in this case (1.5 L/min x 2 µg/L or 3 
µg/min) will be lower than that in Scenario 1 (1.5 
L/min x 3 µg/L or 4.5 µg/min). Again, the rate of 
elimination may also be estimated using Equation 
2: 
 
Portal Vein/
Hepatic Artery Hepatic Vein
Liver
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Cin: 4 µg/L
Cout: 2 µg/L
 
 
Figure 3: The metabolism of a hypothetical drug in one 
single pass through the liver based on Scenario 2 (a 
decrease in the inlet drug concentration; see text for 
details). 
dAe /dt = CL × C = 0.75 L/min× 4 μg/L = 3.0 μg/min
 
This observation indicates that the rate of 
elimination is dependent on the blood concentration 
of the drug, whereas CL is independent of blood 
concentration for a drug with linear 
pharmacokinetics. 
Scenario 3: a change in the clearance 
For this scenario, we shall change the CL of the 
drug and keep the inlet concentration the same as 
that in Scenario 1. Based on Equation 7, CL is 
dependent on Q and E. Additionally, E is dependent 
on Q, fub, and CLint (Equation 6), with the latter 
being dependent on VMAX and KM (Equation 4). A 
change in any of the determinants of CL, which are 
Q, fub, VMAX and KM (Equation 8), can potentially 
alter CL. Let us assume that the VMAX of the drug is 
increased by a factor of 2 from 1.5 mg/min to 3 
J Pharm Pharmaceut Sci (www.cspsCanada.org) 9(1):113-118, 2006 
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mg/min as a result of an interacting drug. This in 
turn results in a two-fold increase in CLint from 15 
L/min to 30 L/min: 
CLint ≈
VMAX
KM
≈
3.0
0.1
= 30 L/min  
 The increased CLint will cause an increase in E 
and CL as demonstrated in Figure 4 and by 
Equations 6 and 7: 
E ≈
fub ⋅ CLint
Q + fub ⋅ CLint
=
0.1× 30
1.5 + (0.1× 30)
= 0.67  
CL =1.5 × 0.67 =1.0 L/min  
 
Portal Vein/
Hepatic Artery Hepatic Vein
Liver
Metabolite
Q: 1.5 L/min
Cin: 6 µg/L
Cout: 2 µg/L
 
 
Figure 4: The metabolism of a hypothetical drug in one 
single pass through the liver based on Scenario 3 (an 
increase in the clearance; see text for details). 
 
 Figure 4 also clearly shows that the rate of 
elimination of the drug in this case is 6 µg/min (1.5 
L/min x 4 µg/mL). As in the previous scenarios, the 
rate of elimination can also be calculated using 
Equation 2: 
dAe /dt = CL × C =1.0 L/min× 6 μg/L = 6.0 μg/min
 
This scenario shows that when CL is changed, the 
rate of elimination of the drug changes 
proportionally. 
Summary of scenarios 
The three scenarios discussed above for a drug with 
linear pharmacokinetics suggest the following 
conclusions: 
1. When the blood concentration of the drug 
changes, CL remains unchanged, whereas the 
rate of elimination of the drug changes 
proportionally. In other words, the change in 
the rate of elimination does not affect CL 
(Scenario 2). This shows the dependency of the 
rate of elimination to the blood concentration. 
Further, it shows the independence of CL from 
the rate of elimination. 
2. When the blood concentration is kept constant 
and one of the determinants of CL is changed, 
the change in CL is proportionally reflected in a 
change in the rate of elimination, indicating the 
dependency of the rate of elimination on the CL 
and its determinants (Scenario 3). 
3. Consequently, the rate of elimination is 
dependent on both the CL and blood 
concentration of the drug. Although CL is not 
affected by the rate of elimination, it is 
dependent on its determinants CLint, fub, and Q.  
Coming back to the-chicken-and-the-egg dilemma, 
it is clear that there is no dilemma regarding the rate 
of elimination and CL; it is the rate of elimination 
that is dependent on CL and not vice versa. 
Therefore, although both Equations 1 and 2 are 
mathematically correct, only Equation 2 is 
physiologically valid. Researchers often use 
Equation 1 to estimate CL. However, it should not 
be forgotten that it is CL that determines the rate of 
elimination. 
THE RELATIONSHIPS AMONG OTHER 
PHARMACOKINETIC PARAMETERS 
As the above discussion suggests, CL is a major PK 
parameter that is related to the efficiency of the 
eliminating organs, such as the liver and kidneys, to 
remove the drug from the body. Another major PK 
parameter, which is at the same level of importance 
as CL, is the volume of distribution (V), which is an 
indication of the extent of the distribution of the 
drug within the body. Similar to CL, V is 
determined by the physiological parameters of the 
patient and the physicochemical characteristics of 
the drug.  The volume of distribution of drugs at 
steady state (VSS) is dependent on the volumes of 
blood (VB) and tissue (VT) and free fractions of the 
drug in blood (fub) and tissues (fut) according to the 
following equation (6): 
VSS = VB +
fub
fut
VT  (9) 
 Both V and CL are independent parameters, 
meaning that a change in one does not necessarily 
result in a change in the other parameter, although 
there may be situations when a change in an 
underlying physiologic factor would affect both 
parameters (such as a change in fub). 
 A third major PK parameter is the elimination 
half life (t1/2) or rate constant (k). However, it 
should be noted that, in contrast to CL and V, t1/2 or 
J Pharm Pharmaceut Sci (www.cspsCanada.org) 9(1):113-118, 2006 
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k does not represent any single physiological 
process. Instead, it is a composite parameter, 
reflecting both CL and V processes (2). Therefore, 
although these three major parameters are 
mathematically related to each other, one should be 
aware that t1/2 or k is dependent on both CL and V 
and not vice versa.  Therefore, although one may 
use the mathematical relationship presented in 
Equation 10 to estimate CL, one should be aware 
that the proper equations describing the 
interdependency of these three parameters are 
presented by Equations 11 and 12: 
CL = k ⋅V  (10) 
k =
CL
V
 (11) 
t1/ 2 =
0.693V
CL
 (12) 
 
 
 This issue has been discussed in detail in a 
recent article (2), hence will not be covered in more 
detail here. 
CONCLUSIONS 
The arguments presented here are summarized in 
Figure 5 in terms of hierarchy of the major 
pharmacokinetic parameters (constants) and their 
interdependence. Furthermore, the effects of these 
kinetic parameters on the blood concentrations and 
elimination rate after a single intravenous dose are 
demonstrated.  
 Although the hypothetical drug used here only 
underwent hepatic metabolism, the principles 
discussed here are equally applicable for drugs 
undergoing renal and/or hepatic elimination. When 
different organ clearances are involved in the drug 
elimination, the total CL will be a summation of the 
individual clearances. This, however, does not 
change the dependency of the rate of elimination on 
total CL. 
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Figure 5: The relationship among physiological and PK parameters for a hypothetical drug eliminated only by hepatic 
metabolism after administration of a single intravenous bolus dose.  
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ABBREVIATION LIST 
C Blood Concentration 
Cu Unbound Concentration 
Cin Inlet Concentration 
Cout Outlet Concentration 
CL Clearance 
CLint Intrinsic Clearance 
dAe/dt Rate of Elimination 
E Hepatic Extraction Ratio 
fub Drug Unbound Fraction in Blood  
fut Drug Unbound Fraction in Tissue 
k Elimination Rate Constant  
KM Michaelis-Menten Constant 
Q Hepatic Blood Flow 
t1/2 Elimination Half Life 
V Volume of Distribution 
VB Blood Volume 
VMAX Maximum Rate of Metabolism 
VSS Volume of Distribution at Steady State 
VT Tissue Volume 
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